Dr. John Cush RheumNow
4 years 5 months ago
Heart Risks Elevated in RA Patients Despite Biologic Tx
Hopes that biologic drugs for RA would cancel the extra cardiovascular risks normally seen with the disease dimmed a little in the face of findings from a population-based study from Scandinavia.
https://t.co/qUYG3U2Ind https://t.co/oCpNnDmxIX
Dr. John Cush RheumNow
4 years 5 months ago
RheumNow's PsA Campaign with enhanced coverage of Psoriatic Disease is sponsored by Janssen. All content is chosen by RheumNow + its faculty. #PsAlways https://t.co/sjwVaNjK6x
Dr. John Cush RheumNow
4 years 5 months ago
Systematic lit review of 5694 CTD pts (SLE, RA, IIM, SSc) admitted to the ICU shows overall risk of mortality was 33%. ICU admits mainly for sepsis (43%), flares(40%). Mortality risk was 70% in IIM, 40% SSc, 35% SLE subgroup, 20% RA. https://t.co/ubVujkLCNy https://t.co/nnJdO36imK
Dr. John Cush RheumNow
4 years 5 months ago
Retrospective cohort hospital study of 228 children with MIS-C; 215 patients (median age 8 yrs, 63% boys) shows that orticosteroid monotherapy is a reasonable management option for a subset of patients with MIS-C, particularly those with mild disease https://t.co/HLSR5zOseU https://t.co/5z7I9SVcxI
Dr. John Cush RheumNow
4 years 5 months ago
#PsA Biologic initiation was associated with a SMALL drop in NSAIDs (51.1 to 42.5%); glucocorticoids (57.4 to 46.9%) and opioids (38.1 to 33.8%) (Initial vs 12 mos later). Pain Rx use study in 5681 PsA, 2180 AS, & 34,047 RA pts #PsAlways https://t.co/wyrT9CVNq8 https://t.co/8vl7e2a63n
Dr. John Cush RheumNow
4 years 5 months ago
Korean study shows #RA is assoc w/ a risk of primary open-angle glaucoma, esp within 2 yrs of Dx & if >75 yrs. Study of 2049 older incident RA pts; POAG risk higher in RA than the matched controls (HR 1.44), 1st 2 yrs (HR 1.83), >75 yrs (HR 2.12) https://t.co/IvPw5InSis https://t.co/dkrK6RvRKE
With overwhelming support from some 200 experts worldwide, dosing of methotrexate (MTX) for psoriasis should start at 15 mg/week for most adults, though lower in those considered "vulnerable" and in children, according to a new consensus statement.
Dr. John Cush RheumNow
4 years 5 months ago
Danish study of opioids in psoriasis (n 4016), PsA (847) & controls (3490). Opioid Use within 12 months seen in 9% general population, 14.2% psoriasis without PsA, & 22.7% concomitant PsA pts. Joint pain incr analgesic use (OR 3.72) #PsAlways https://t.co/WKrA8sChyN https://t.co/9FLq4mKz7V
Throughout the month of April 2022, RheumNow is introducing a new approach to education and information sharing – a campaign devoted to a single disease. Our first campaign is entitled PsA All the Way: RheumNow will escalate awareness on this topic, its unmet needs, clarify advances and discuss key advances and modern disease management. We're featuring guest bloggers, hosting Tuesday Night Rheumatology, posting slides and videos, and much more
Dr. John Cush RheumNow
4 years 5 months ago
The Effect of Socioeconomic Status on Lupus Outcomes
Socioeconomic status (SES) often associates with poorer outcomes in systemic lupus erythematosus (SLE) patients; and a current study suggests this is unrelated to healthcare access issues.
https://t.co/J1BMlsakGN https://t.co/BNhCN89Pqv
The incidence and mortality of cancer among autoimmune diseases (AID) was studied in a large Chinese cohort, demonstrating that while onset time and risks vary, there is an increased risk of malignancy in AID.
Hopes that biologic drugs for rheumatoid arthritis (RA) would cancel the extra cardiovascular risks normally seen with the disease dimmed a little in the face of findings from a population-based study from Scandinavia.
Dr. John Cush RheumNow
4 years 5 months ago
Japanese study using Mendelian randomization (MR) analysis of the association between coffee consumption, gout & uric acid levels - showing coffee consumption can causally reduce gout risk (OR = 0.50), independent of SUA levels https://t.co/ymovYj5y40 https://t.co/uI7OqY9FcU
